|Table of Contents|

The targeted therapy progress of advanced non-small cell lung cancer with ALK fusion gene positive

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2019 03
Page:
529-533
Research Field:
Publishing date:

Info

Title:
The targeted therapy progress of advanced non-small cell lung cancer with ALK fusion gene positive
Author(s):
Xu Airu; Ma Wei
Department of Respiratory Medicine，Guangzhou First People's Hospital Affiliated to Guangzhou Medical University，Guangdong Guangzhou 510000，China.
Keywords:
anaplastic lymphoma kinase fusion gene; anaplastic lymphoma kinase gene rearrangements; non-small cell lung cancer; ALK tyrosine kinase inhibitors
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2019.03.042
Abstract:
In the past decade，there has been a major pattern transformation in the treatment of advanced non-small cell lung cancer(NSCLC).The presence of key oncogenic mutations（such as driving gene mutations and chromosomal rearrangements） has made that targeted therapies have a higher sensitivity compared with traditional cytotoxic chemotherapy.Fusion mutations in the anaplastic lymphoma kinase（ALK） gene and the echinoderm microtubule-associated protein-4(EML4)gene were first discovered in patients with NSCLC in 2007.Subsequent studies confirmed that the ALK-EML4 fusion mutation positive non-small-cell lung cancer(ALK+NSCLC) showed sensitivity to crizotinib treatment.With the subsequent development of a series of targeted therapeutic new drugs，the ALK+ NSCLC targeted therapy was pushed to the top.This review summarizes the molecular biology pathogenesis，epidemiological characteristics，and detection methods of ALK+NSCLC，summarizing the results of important clinical trials of inhibitors and reviewing the latest advances in ALK+NSCLC inhibitor resistance mechanisms and brain metastases.

References:

［1］Golding B，Luu A，Jones R，Viloria-Petit AM.The function and therapeutic targeting of anaplastic lymphoma kinase(ALK)in non-small cell lung cancer(NSCLC)［J］.Mol Cancer，2018，17(1)：52.
［2］Lin JJ，Zhu VW，Yoda S，et al.Impact of EML4-ALK variant on resistance mechanisms and clinical outcomes in ALK-positive lung cancer［J］.Journal of Clinical Oncology，2018，36(12)：1199-1206.
［3］Rikova K，Guo A，Zeng Q，et al.Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer［J］.Cell，2007，131(6)：1190-1203.
［4］Takeuchi K，Choi YL，Togashi Y，et al.KIF5B-ALK，a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer［J］.Clin Cancer Res，2009，15(9)：3143-3149.
［5］Soda M，Choi YL，Enomoto M，et al.Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer［J］.Nature，2007，448(7153)：561-566.
［6］Manabu Sodaab，Shuji Takadaa，Kengo Takeuchic，et al.A mouse model for EML4-ALK-positive lung cancer［J］.The National Academy of Sciences of the USA，2008，105(50)：19893-19897.
［7］Erik Thunnissen LB，Manfred Dietel.EML4-ALK testing in non-small cell carcinomas of the lung：A review with recommendations［J］.Virchows Arch，2012，461：245-257.
［8］Shaw AT，Yeap BY，Mino-Kenudson M，et al.Clinical features and outcome of patients with non-small cell lung cancer who harbor EML4-ALK［J］.Journal of Clinical Oncology，2009，27(26)：4247-4253.
［9］Rodney E，Shackelford MV，Kim Mayhall，et al.ALK-rearrangements and testing methods in non-small cell lung cancer：A review［J］.Genes & Cancer，2014，5(1-2)：114-128.
［10］Conklin CM，Craddock KJ，Have C.Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent［J］.Journal of Thoracic Oncology，2013，8(1)：45-51.
［11］Zhang YG，Jin ML，Li L，et al.Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH，immunohistochemistry，and real-time quantitative RT-PCR on paraffin-embedded tissues［J］.PLoS One，2013，8(5)：e64821.
［12］Vendrell JA，Taviaux S，Beganton B，et al.Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches［J］.Sci Rep，2017，7(1)：12510.
［13］Hiley CT，Le Quesne J，Santis G，et al.Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease［J］.The Lancet，2016，388(10048)：1002-1011.
［14］Camidge DR，Bang YJ，Kwak EL，et al.Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer：Updated results from a phase 1 study［J］.The Lancet Oncology，2012，13(10)：1011-1019.
［15］Fiona Blackhall DRC，Alice T Shaw.Final results of the large-scale multinational trial PROFILE 1005：Efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small cell lung cancer［J］.BMJ，2017，2：e000219.
［16］Nishio M，Kim DW，Wu YL，et al.Crizotinib versus chemotherapy in asian patients with advanced ALK-positive non-small cell lung cancer［J］.Cancer Res Treat，2017，50（3）：691-700.
［17］Zhou J，Zheng J，Zhang X，et al.Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment［J］.BMC Cancer，2018，18(1)：10.
［18］Kim DW，Mehra R，Tan DSW，et al.Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer(ASCEND-1)：Updated results from the multicentre，open-label，phase Ⅰ trial［J］.The Lancet Oncology，2016，17(4)：452-463.
［19］Tan DS，Araujo A，Zhang J，et al.Comparative efficacy of ceritinib and crizotinib as initial ALK-targeted therapies in previously treated advanced NSCLC：An adjusted comparison with external controls［J］.Journal of Thoracic Oncology，2016，11(9)：1550-1557.
［20］Soria JC，Tan DSWT，Chiari R，et al.First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small cell lung cancer(ASCEND-4)：A randomised，open-label，phase 3 study［J］.Lancet，2017，389：917.
［21］Shaw AT，Kim TM，Crinò L，et al.Ceritinib versus chemotherapy in patients with ALK-rearranged non-small cell lung cancer previously given chemotherapy and crizotinib(ASCEND-5)：A randomised，controlled，open-label，phase 3 trial［J］.The Lancet Oncology，2017，18(7)：874-886.
［22］Cho BC，Kim DW，Bearz A，et al.ASCEND-8：A Randomized phase 1 study of ceritinib，450 mg or 600 mg，taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase(ALK)-rearranged metastatic non-small cell lung cancer(NSCLC)［J］.Journal of Thoracic Oncology，2017，12(9)：1357-1367.
［23］Seto T，Kiura K，Nishio M，et al.CH5424802(RO5424802)for patients with ALK-rearranged advanced non-small-cell lung cancer(AF-001JP study)：A single-arm，open-label，phase 1-2 study［J］.The Lancet Oncology，2013，14(7)：590-598.
［24］Shirish M Gadgeel LG，Gregory J Riely.Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer(AF-002JG)：Results from the dose-finding portion of a phase 1/2 study［J］.Lancet Oncol，2014，15：1119-1128.
［25］Hida T，Nokihara H，Kondo M，et al.Alectinib versus crizotinib in patients with ALK-positive non-small cell lung cancer(J-ALEX)：An open-label，randomised phase 3 trial［J］.The Lancet，2017，390(10089)：29-39.
［26］Peters S，Camidge DR，Shaw AT，et al.Alectinib versus crizotinib in untreated ALK-positive non-small cell lung cancer［J］.The New England Journal of Medicine，2017，377(9)：829-838.
［27］Ou SHI，Ahn JS，De Petris L，et al.Alectinib in crizotinib-refractory ALK-rearranged non-small cell lung cancer：A phase Ⅱ global study［J］.Journal of Clinical Oncology，2016，34(7)：661-668.
［28］D Ross Camidge D-WK，Marcello Tiseo.Exploratory analysis of brigatinib activity in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer and brain metastases in two clinical trials［J］.American Society of Clinical Oncology，2018，36（26）：2693-2701.
［29］Dong-Wan Kim MT，Myung-Ju Ahn.Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer：A randomized，multicenter phase Ⅱ trial［J］.Journal of Clinical Oncology，2017，35：2490-2498.
［30］Zou HY，Friboulet L，Kodack DP，et al.PF-06463922，an ALK/ROS1 inhibitor，overcomes resistance to first and second generation ALK inhibitors in preclinical models［J］.Cancer Cell，2015，28(1)：70-81.
［31］Johnson TW，Richardson PF，Bailey S，et al.Discovery of(10R)-7-amino-12-fluoro-2，10，16-trimethyl-15-oxo-10，15，16，17-tetrahydro-2H-8，4-(m etheno) pyrazolo［4，3-h］［2，5，11］-benzoxadiazacyclotetradecine-3-carbonitrile(PF-06463922)，a macrocyclic inhibitor of anaplastic lymphoma kinase(ALK) and c-ros oncogene 1(ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations［J］.J Med Chem，2014，57(11)：4720-4744.
［32］Shaw AT，Felip E，Bauer TM，et al.Lorlatinib in non-small cell lung cancer with ALK or ROS1 rearrangement：An international，multicentre，open-label，single-arm first-in-man phase 1 trial［J］.The Lancet Oncology，2017，18(12)：1590-1599.
［33］CG Woo SS，SW Kim.Annals of oncology advance access published december 29，2016［J］.European Society for Medical Oncology，2016，88：5505-5550.
［34］Le T，Gerber DE.ALK alterations and inhibition in lung cancer［J］.Semin Cancer Biol，2017，42：81-88.
［35］Van Der Wekken AJ，Saber A，Hiltermann TJ.Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer，a review of the literature［J］.Crit Rev Oncol Hematol，2016，100：107-116.
［36］Ji C，Zhang L，Cheng Y，et al.Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer［J］.Cancer Biol Ther，2014，15(5)：570-577.
［37］Metro G，Lunardi G，Floridi P，et al.CSF concentration of crizotinib in two ALK-positive non-small cell lung cancer patients with CNS metastases deriving clinical benefit from treatment［J］.Journal of Thoracic Oncology，2015，10(5)：e26-e27.
［38］Gainor JF，Dardaei L，Yoda S，et al.Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer［J］.Cancer Discov，2016，6(10)：1118-1133.
［39］Solomon BJ，Cappuzzo F，Felip E，et al.Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced alk-positive non-small cell lung cancer：Results from PROFILE 1014［J］.Journal of Clinical Oncology，2016，34(24)：2858-2865.
［40］Gettinger SN，Bazhenova LA，Langer CJ，et al.Activity and safety of brigatinib in ALK-rearranged non-small cell lung cancer and other malignancies：A single-arm，open-label，phase 1/2 trial［J］.The Lancet Oncology，2016，17(12)：1683-1696.
［41］Zou HY，Li Q，Engstrom LD，et al.PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations［J］.Proc Natl Acad Sci USA，2015，112(11)：3493-3498.

Memo

Memo:
广州市科技计划项目（编号：2011J4100027）
Last Update: 2018-12-29